@IMDConline profile picture
IMDC @IMDConline

International mRCC Database Consortium #IMDC #kcsm

Joined December 2019
  • Tweets 133
  • Following 0
  • Followers 242
4 Photos and videos
IMDC retweeted
Ziad Bakouny, MD, MSc@ZiadBakouny
21 Oct 2022
Post-call in the CCU, so late in sharing this but thrilled to see our work on upfront cytoreductive nephrectomy in metastatic RCC now published in @EUplatinum Huge thanks to co-first author @TalalZarif1 and co-senior @Wanling50578056 @DrDanielHeng @DrChoueiri & @IMDConline (1/1)
Toni Choueiri, MD
@DrChoueiri
20 Oct 2022
JUST IN: Cytoreductive Nephrectomy for Metastatic RCC Treated with Immune Checkpoint Inhibitors or Targeted Therapy: The @IMDConline does it again ! #IMDC @DrDanielHeng with @TalalZarif1 @ZiadBakouny @ShaanDudani et al in @EUplatinum secure-web.cisco.com/1nOqqWr…
3
6
55
IMDC retweeted
Toni Choueiri, MD
@DrChoueiri
20 Oct 2022
JUST IN: Cytoreductive Nephrectomy for Metastatic RCC Treated with Immune Checkpoint Inhibitors or Targeted Therapy: The @IMDConline does it again ! #IMDC @DrDanielHeng with @TalalZarif1 @ZiadBakouny @ShaanDudani et al in @EUplatinum secure-web.cisco.com/1nOqqWr…
6
99
266
IMDC retweeted
Sumanta K. Pal, MD, FASCO
@montypal
2 Sep 2021
Phenomenal work from @anobelodisho collaborating with @IMDConline @DrChoueiri @DrDanielHeng @gorejohn - this will be a useful tool for so many!
This tweet is unavailable
2
14
IMDC retweeted
Chun Loo Gan@ChunLGan
8 May 2021
Just out in EJC: Outcomes of pts treated with 1L IO agents who were trial ineligible. Big thanks to all patients, Alberta Immunotherapy Database @dmeyzie IgorStukalin, @IMDConline collaborators and my mentor @DrDanielHeng @DrChoueiri @montypal @OncoAlert sciencedirect.com/science/ar…
3
31
76
IMDC retweeted
Daniel Heng@DrDanielHeng
8 May 2021
Alberta Immunotherapy Database-led study shows pts that are trial ineligible by common criteria have poorer associated outcomes to 1st line IO in #kidneycancer #lungcancer #melanoma so expectations need to be tempered. @albertacancer #RWE @IMDConline Proud of @ChunLGan🇦🇺🇨🇦🇲🇾!
Chun Loo Gan@ChunLGan
8 May 2021
Just out in EJC: Outcomes of pts treated with 1L IO agents who were trial ineligible. Big thanks to all patients, Alberta Immunotherapy Database @dmeyzie IgorStukalin, @IMDConline collaborators and my mentor @DrDanielHeng @DrChoueiri @montypal @OncoAlert sciencedirect.com/science/ar…
3
9
31
IMDC@IMDConline
14 Mar 2021
Congratulations @DrJeffreyGraham!!
European Urology Oncology
@EurUrolOncol
13 Mar 2021
This month’s @EurUrolOncol #SoMe Award is presented to… Outcomes of Patients with Metastatic RCC Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors euoncology.europeanurology.c… Congrats to @DrJeffreyGraham, Amishi Y. Shah & coauthors! #kidneycancer
5
IMDC retweeted
Sumanta K. Pal, MD, FASCO
@montypal
7 Mar 2021
For my colleagues in #GeriOnc, nice article led by @DVAraujoMD & @ShaanDudani looking at age & outcome w ICIs in #kidneycancer. The @IMDConline strikes again (thx @DrDanielHeng @DrChoueiri) suggesting no diff in OS based on age; RR diff in 1L intriguing?
15
33
IMDC retweeted
Sumanta K. Pal, MD, FASCO
@montypal
5 Mar 2021
Woderful work by @lalaniMD using the @IMDConline database w @DrDanielHeng @DrChoueiri et al! The IMDC is a gift that keeps on giving ... valuable clinical insights. @ZiadBakouny @ShaanDudani
Neeraj Agarwal, MD, FASCO
@neerajaiims
4 Mar 2021
Just in @JAMAOnc :High BMI associated with improved OS in patients with mRCC #kidneycancer treated with PD-1/PD-L1i👉Obesity paradox persists with IOs as with VEGFi bit.ly/3uVpvGs Congrats 👏👏to Alykhan @lalaniMD @ZiadBakouny @DrDanielHeng @DrChoueiri @OncoAlert
7
21
IMDC retweeted
Ziad Bakouny, MD, MSc@ZiadBakouny
4 Mar 2021
Thrilled to see our paper out in @JAMAOnc! @lalaniMD @DrChoueiri @DrDanielHeng @ShaanDudani @FDonskov @IMDConline The IO sequel to the original obesity paradox in mRCC! @OncoAlert @urotoday @OncLive
Neeraj Agarwal, MD, FASCO
@neerajaiims
4 Mar 2021
Just in @JAMAOnc :High BMI associated with improved OS in patients with mRCC #kidneycancer treated with PD-1/PD-L1i👉Obesity paradox persists with IOs as with VEGFi bit.ly/3uVpvGs Congrats 👏👏to Alykhan @lalaniMD @ZiadBakouny @DrDanielHeng @DrChoueiri @OncoAlert
1
7
44
IMDC retweeted
Aly-Khan Lalani@lalaniMD
5 Mar 2021
As always, thanks to important contributions by international investigators, sites, and *most importantly* patients to team efforts like @IMDConline @montypal @DrVaishampayan @Wanling50578056 @steinharterjack @JustinFleische6 @PierVitaleNuzzo @nbasappaCCI more! 👏👏👏
1
2
7
IMDC retweeted
Andrew Schmidt@dr_aschmidt
13 Feb 2021
4/ Looking at all patients with mRCC, incorporating the very favorable category into IMDC criteria, we can identify 4 distinct prognostic groups. @DrBryanChan @JeffreyCGoh1
1
2
7
IMDC retweeted
Yüksel Ürün
@DrYukselUrun
13 Feb 2021
Outcomes of 1st line combos in inter/poor-risk mRCC from @IMDConline @ChunLGan 🔶Higher ORR, lower PD with IO-VEGF/TKI 🔶Similar oncological outcomes! 🔶Higher irAEs with nivo-ipi but may predict better outcomes! @OncoAlert #GU21
10
19
IMDC retweeted
Andrew Schmidt@dr_aschmidt
13 Feb 2021
RCC has diverse outcomes: proud to be part of work @ASCO #GU21 from @DrChoueiri @DrDanielHeng @IMDConline where we identify a very favorable prognostic group of patients meetinglibrary.asco.org/reco… @ZiadBakouny @ShaanDudani @neerajaiims

2
8
23
IMDC retweeted
Toni Choueiri, MD
@DrChoueiri
13 Feb 2021
Now with @ChunLGan @IMDConline with real-word evidence showing equivalent OS and TTNT between IO-IO and IO-VEGF regimens in poor/interm. risk mRCC !! @ASCO #GU21 @ASCO_pubs @ASCOPost @DrDanielHeng @montypal @TiansterZhang @ZiadBakouny @AlbigesL @urotoday @OncoAlert @DanaFarber
10
29
IMDC retweeted
Jeffrey Graham@DrJeffreyGraham
13 Feb 2021
Our @IMDConline analysis on the effectiveness of first-line ICI based therapy in advanced non-clear cell RCC! @DrDanielHeng @DrChoueiri @montypal #GU21
1
10
21
IMDC retweeted
Chun Loo Gan@ChunLGan
30 Jan 2021
In this real-world study, Cabozantinib has activity across 1L-4L settings in #mRCC. Dose reduction for AEs was associated with better outcomes. Thanks to all @IMDConline collaborators! onlinelibrary.wiley.com/doi/… @DrDanielHeng @DrChoueiri @ShaanDudani @FDonskov @DrBenTran @montypal
2
10
41
IMDC retweeted
Nils Kröger@KrgerMd
22 Jan 2021
Replying to @OncoAlert @OncEd @JAMANetworkOpen @JAMAOnc
Congrats @ShaanDudani and @DrDanielHeng for this important work! Thanks for including us.
1
4
IMDC retweeted
Shaan Dudani@ShaanDudani
22 Jan 2021
Just out in @JAMANetworkOpen: Sites of metastasis vary by histology in mRCC and are associated with OS. Thanks to all @IMDConline collaborators! @DrDanielHeng @DrChoueiri @ChunLGan @g_develasco @CPRT65 @FDonskov @montypal @ravikanesvaran @NeilReaumeMD jamanetwork.com/journals/jam…
6
58
144
IMDC retweeted
JAMA Network Open@JAMANetworkOpen
22 Jan 2021
Cohort study finds metastases vary between histologic subtypes of mRCC, sites of metastatic involvement are associated with survival: ccRCC = ↑ lung, brain, adrenal, pancreas mets pRCC = ↑ lymph node mets chrRCC = ↑ liver mets @ShaanDudani @DrDanielHeng ja.ma/3c37XkC
10
18
Great work to see sites of metastasis with survival outcomes in @IMDConline. Good reference for oncologists who treat #kidneycancer.
Shaan Dudani@ShaanDudani
22 Jan 2021
Just out in @JAMANetworkOpen: Sites of metastasis vary by histology in mRCC and are associated with OS. Thanks to all @IMDConline collaborators! @DrDanielHeng @DrChoueiri @ChunLGan @g_develasco @CPRT65 @FDonskov @montypal @ravikanesvaran @NeilReaumeMD jamanetwork.com/journals/jam…
3
11
Load more